Moderna, Inc. (NASDAQ:MRNA) Receives $42.13 Average PT from Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have been assigned an average recommendation of “Reduce” from the seventeen analysts that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $42.1333.

Several analysts recently commented on MRNA shares. Royal Bank Of Canada lifted their price objective on Moderna from $38.00 to $45.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. Morgan Stanley increased their target price on Moderna from $33.00 to $39.00 and gave the company an “equal weight” rating in a report on Wednesday, July 8th. Citigroup raised their target price on Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Bank of America upped their price target on shares of Moderna from $34.00 to $38.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. Finally, UBS Group reaffirmed an “overweight” rating on shares of Moderna in a research report on Monday, August 3rd.

Insider Activity at Moderna

In other Moderna news, Director Noubar Afeyan sold 9,263 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the sale, the director directly owned 3,924 shares of the company’s stock, valued at approximately $183,800.16. This represents a 70.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider owned 67,468 shares in the company, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 119,406 shares of company stock worth $5,928,762. 10.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Moderna

A number of institutional investors have recently bought and sold shares of MRNA. BlackRock Inc. bought a new position in shares of Moderna in the second quarter worth approximately $2,142,877,000. Capital World Investors bought a new stake in shares of Moderna during the 4th quarter valued at $378,299,000. Alyeska Investment Group L.P. bought a new stake in shares of Moderna during the 4th quarter valued at $95,209,000. Norges Bank bought a new stake in shares of Moderna during the 4th quarter valued at $79,707,000. Finally, Merck & Co. Inc. purchased a new position in shares of Moderna during the 2nd quarter valued at $161,642,545,000. 75.33% of the stock is owned by institutional investors.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved mFLUSIVA, Moderna’s mRNA-based seasonal influenza vaccine, for adults ages 50 and older. It is the first mRNA flu vaccine approved in the United States and Moderna’s fourth FDA-approved product, supporting the company’s effort to diversify beyond COVID-19. The company expects limited retail availability in the coming weeks. US FDA approves first mRNA flu shot from Moderna
• Positive Sentiment: On its second-quarter earnings call, Moderna maintained its 2026 growth target while lowering cost guidance. The combination of preserved revenue expectations and lower spending could improve cash runway and reduce concerns about the company’s post-pandemic revenue decline. Management also highlighted upcoming milestones for flu, oncology and rare-disease programs. Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
• Positive Sentiment: Moderna began a Phase 1 Canadian trial of an investigational mRNA vaccine for Bundibugyo ebolavirus, a strain without an approved vaccine. Although early-stage, the program reinforces the breadth of Moderna’s infectious-disease platform and its partnerships with CEPI and Canadian public-health authorities. Moderna Starts Phase 1 Canada Trial For Bundibugyo Ebola mRNA Vaccine
• Neutral Sentiment: The flu approval is a meaningful commercial opportunity, but Moderna still needs CDC recommendations, distribution and physician adoption to translate the regulatory win into material revenue. The initial authorization is limited to adults 50 and older, with established flu vaccines already competing for the upcoming season. Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain
• Negative Sentiment: Investors continue to face substantial execution risk: COVID-related revenue has fallen sharply from pandemic highs, Moderna remains loss-making, and future valuation depends heavily on successful Phase 3 oncology results and broader pipeline commercialization. Some brokerages maintain a “Reduce” view, limiting the immediate impact of the positive headlines.

Moderna Trading Up 9.9%

Shares of MRNA stock opened at $59.17 on Thursday. Moderna has a 12-month low of $22.28 and a 12-month high of $85.60. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average is $60.28 and its 200 day moving average is $53.12. The stock has a market capitalization of $23.62 billion, a P/E ratio of -7.41 and a beta of 0.91.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.13) EPS. Research analysts expect that Moderna will post -6.2 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.